Business Context and Reporting Period
Company: Hyseq, Inc. (operating as Hyseq Pharmaceuticals, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2001
Business Overview: Hyseq is a biopharmaceutical company focused on discovering and developing therapeutic protein-based products using its proprietary signature-by-hybridization platform. The company maintains a large database of full-length human gene sequences. In October 2001, the company reorganized to separate its sequencing-by-hybridization (SBH) technology into a majority-owned subsidiary, Callida Genomics, Inc., while continuing its biopharmaceutical operations under the Hyseq Pharmaceuticals name. Key product candidates include alfimeprase (acquired via collaboration with Amgen in January 2002) for peripheral arterial occlusion.
Key Financial Metrics
| Metric | 2001 | 2000 | 1999 |
|---|---|---|---|
| Contract Revenues | $24.6 million | $15.6 million | $6.4 million |
| Net Loss | $(36.5) million | $(22.3) million | $(18.5) million |
| Loss Per Share (Basic/Diluted) | $(2.26) | $(1.65) | $(1.43) |
| Research & Development Expenses | $46.5 million | $29.0 million | $18.2 million |
| General & Administrative Expenses | $13.5 million | $9.3 million | $8.1 million |
| Cash and Cash Equivalents (Year End) | $12.3 million | $2.7 million | $13.7 million |
| Working Capital | $(1.8) million | $(2.6) million | $22.1 million |
| Accumulated Deficit | $(108.4) million | $(71.9) million | $(49.7) million |
Material Changes vs. Prior Period
- Revenue Growth: Contract revenues increased 58% to $24.6 million, driven primarily by the BASF collaboration ($22.4 million in 2001 vs. $11.7 million in 2000). Revenue from Chiron decreased significantly as the initial gene screening phase concluded.
- Expense Increase: Total operating expenses rose 59% to $60.8 million. R&D expenses increased $17.5 million due to expanded biopharmaceutical research, new scientific personnel, and facility expansion. G&A expenses increased $4.1 million, largely due to senior management compensation and recruiting.
- Liquidity Position: Despite a net loss of $36.5 million, cash balances increased from $2.7 million to $12.3 million. This was achieved through a $20.7 million private equity placement (PIPE), a $20.0 million drawdown on a line of credit from the Chairman (converted to stock), and an $8.0 million settlement payment from Affymetrix.
- Capital Structure: The company issued 2.2 million shares to convert a $20 million debt obligation from the Chairman and 3.0 million shares in the August 2001 private placement.
Guidance, Outlook, and Risks
- Outlook: Management expects operating expenses to increase in 2002 to support clinical trials for alfimeprase, facility build-outs, and SBH technology development. The company anticipates continuing to incur significant net losses for the foreseeable future.
- Financing Needs: The company explicitly states it requires substantial additional financing to fund operations. It has implemented a hiring freeze and deferred capital expenditures pending new funding. The Chairman has agreed to provide additional financing if necessary.
- Key Risks:
- Liquidity: Dependence on external financing; inability to raise funds could force curtailment of operations.
- Development Risk: No products are currently marketed; all candidates are in pre-clinical or early clinical stages. Pre-clinical success does not guarantee human clinical success.
- Collaboration Dependence: Revenue is heavily reliant on a few partners (BASF accounted for 91% of 2001 revenue). Termination of these agreements would materially harm the business.
- Intellectual Property: Success depends on obtaining and defending patents; the utility of gene patents is subject to regulatory scrutiny.
- Subsequent Events: In January 2002, the company entered a collaboration with Amgen to develop alfimeprase and with Intel for DNA detection technology. In February 2002, the company drew down $4.0 million on its Chairman's line of credit.
Investor Verification Checklist
- Cash Runway: Verify current cash burn rate against the $12.3 million cash balance to determine the timeline for the next required financing round.
- BASF Contract Status: Confirm the status of the BASF collaboration, which generated 91% of 2001 revenue, and any potential risks to its renewal or performance milestones.
- Alfimeprase Progress: Monitor the initiation and results of Phase 1 clinical trials for alfimeprase, scheduled to begin in Q2 2002.
- Chairman Financing: Review the terms and availability of the remaining $16 million on the Chairman's line of credit and any conditions attached to further funding.
- Facility Leases: Assess the financial impact of the significant new lease obligations (approx. $93 million in future commitments) relative to current revenue generation.